Anxioselective anxiolytics: on a quest for the Holy Grail
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
The discovery of “benzodiazepine receptors” provided the impetus to discover and develop anxioselective anxiolytics (“Valium® without the side effects”). The market potential for a GABAA receptor-based anxioselective resulted in multiple compounds entering clinical trials. In contrast to the anxioselective profile displayed in preclinical models, compounds such as bretazenil, TPA023, and MRK 409 produced benzodiazepine-like side effects (sedation, dizziness) in Phase I studies, whereas alpidem and ocinaplon exhibited many of the characteristics of an anxioselective in the clinic. Alpidem was briefly marketed for the treatment of anxiety, but withdrawn because of liver toxicity. Reversible elevations in liver enzymes halted development of ocinaplon in Phase III. The clinical profiles of these two molecules demonstrate that it is possible to develop GABAA receptor-based anxioselectives. However, despite the formidable molecular toolbox at our disposal, we are no better informed about the GABAA receptors responsible for an anxioselective profile in the clinic. Here, I discuss the evolution of a quest, spanning 4 decades, for molecules that retain the rapid and robust anti-anxiety actions of benzodiazepines absent the side effects that limit their usefulness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Which GABAA-receptor subtypes really occur in the brain?
McKernan, R. M., & Whiting, P. J. (1996) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)80023-3 · Cited by 1,222
Benzodiazepine actions mediated by specific γ-aminobutyric acidA receptor subtypes
Rudolph, U., Crestani, F., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Martin, J. R., Bluethmann, H., & Möhler, H. (1999) · Nature · doi:10.1038/44579 · Cited by 1,172
Molecular and neuronal substrate for the selective attenuation of anxiety
Löw, K., Crestani, F., Keist, R., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Rülicke, T., Bluethmann, H., Möhler, H., et al. (2000) · Science · doi:10.1126/science.290.5489.131 · Cited by 946 · cited 1×
“[62] extended these findings, demonstrating that the anxiolytic-like actions of diazepam in both the Skolnick Page 7”
BackgroundMcKernan, R. M., Rosahl, T. W., Reynolds, D. S., Sur, C., Wafford, K. A., Atack, J. R., Farrar, S., Myers, J., Cook, G., Ferris, P., et al. (2000) · Nature Neuroscience · doi:10.1038/75761 · Cited by 944
A new benzodiazepine pharmacology
Möhler, H., Fritschy, J. M., & Rudolph, U. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.1.2 · Cited by 716 · cited 3×
“This enigma was recognized early on [58, 59] and until the recent publication of clinical findings with compounds like TPA 023 and MRK 409 [20, 29] was largely ignored, overshadowed by studies in genetically engineered mice [28, 60].”
BackgroundDias, R., Sheppard, W. F. A., Fradley, R. L., Garrett, E. M., Stanley, J. L., Tye, S. J., Goodacre, S., Lincoln, R. J., Cook, S. M., Conley, R., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1166-05.2005 · Cited by 247 · cited 3×
“Some glaring examples of these discrepant findings include the anxiolytic-like actions of an α3 preferring compound (TP 003) in both wild-type and knockin mice carrying a mutated α2 subunit [63], and the ability of the selective α1 antagonist βCCT (3-t-butoxy-β-carboline) [71] to block the anxiolytic-like (but not the…”
BackgroundStahl, S. M. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0901 · Cited by 88 · cited 1×
“BZs remain in widespread use [1] despite a shift in prescribing practices, with most authorities [2] favoring serotoninspecific reuptake inhibitors (SSRIs) as first-line treatment for generalized anxiety disorder (GAD).”
BackgroundAtack, J. R. (2009) · Advances in Pharmacology · doi:10.1016/s1054-3589(08)57004-9 · Cited by 52 · cited 21×
“A second, shorter trial of ocinaplon in GAD patients demonstrated anxiolysis at 180–240 mg; separation from placebo was apparent as early as the first week of treatment [30].”
BackgroundInfluential
Cited by
Löscher, W., & Klein, P. (2021) · CNS Drugs · doi:10.1007/s40263-021-00827-8 · Cited by 367
Rudolph, U., & Möhler, H. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135947 · Cited by 319
The Benzodiazepine Binding Sites of GABAA Receptors
Sigel, E., & Ernst, M. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.03.006 · Cited by 287
Tzanoulinou, S., García-Mompó, C., Castillo-Gómez, E., Veenit, V., Nacher, J., & Sandi, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094666 · Cited by 56
“However, the quest for understanding the specific involvement of each of these subunits in modulating anxiety is still ongoing [54].”
BackgroundResultBleuer‐Elsner, S., Medam, T., & Masson, S. (2021) · Veterinary Record · doi:10.1002/vetr.453 · Cited by 38
Metadata
- Authors
- Skolnick, P.
- Venue
- Trends in Pharmacological Sciences
- Publisher
- Elsevier BV
- Published
- 2012-11
- Volume
- 33
- Issue
- 11
- Pages
- 611-620
- ISSN
- 0165-6147 (ISSN-L)
- OpenAlex
- W1972515921
- Cited by
- 105
- References
- 8
- FWCI
- 0.55
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anxioselective anxiolytics: on a quest for the Holy Grail. https://app.cochat.ai/papers/10.1016/j.tips.2012.08.003
- The paper
- Skolnick, P. (2012). Anxioselective anxiolytics: on a quest for the Holy Grail. Trends in Pharmacological Sciences. https://doi.org/10.1016/j.tips.2012.08.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.